Mithra Pharmaceuticals SA reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was EUR 7.04 million compared to EUR 11.36 million a year ago. Net loss was EUR 50.47 million compared to EUR 31.25 million a year ago.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.216 EUR | -1.82% | -.--% | -82.78% |
06-11 | Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. acquired Neuralis and Estetra from Mithra Pharmaceuticals SA. | CI |
05-28 | Mithra Delays AGM Amid Monetization Process | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-82.78% | 15.98M | |
+2.99% | 94.76B | |
-3.68% | 37.58B | |
-9.59% | 33.3B | |
+75.35% | 27.92B | |
-13.40% | 15.85B | |
-3.55% | 13.79B | |
-12.21% | 11.51B | |
+188.83% | 10.9B | |
-53.94% | 9.27B |
- Stock Market
- Equities
- MITRA Stock
- News Mithra Pharmaceuticals S.A.
- Mithra Pharmaceuticals SA Reports Earnings Results for the Half Year Ended June 30, 2023